자기자본비율 (ROE)
2013년부터
계산
IQVIA Holdings Inc., ROE, 장기 추세계산
| ROE | = | 100 | × | IQVIA Holdings Inc.에 귀속되는 순이익1 | ÷ | IQVIA Holdings Inc.의 주주에게 귀속되는 자기자본(적자)1 | |
|---|---|---|---|---|---|---|---|
| 2022. 12. 31. | 18.92% | = | 100 | × | 1,091) | ÷ | 5,765) |
| 2021. 12. 31. | 15.99% | = | 100 | × | 966) | ÷ | 6,042) |
| 2020. 12. 31. | 4.65% | = | 100 | × | 279) | ÷ | 6,001) |
| 2019. 12. 31. | 3.18% | = | 100 | × | 191) | ÷ | 6,003) |
| 2018. 12. 31. | 3.86% | = | 100 | × | 259) | ÷ | 6,714) |
| 2017. 12. 31. | 16.14% | = | 100 | × | 1,309) | ÷ | 8,109) |
| 2016. 12. 31. | 1.33% | = | 100 | × | 115) | ÷ | 8,633) |
| 2015. 12. 31. | — | = | 100 | × | 387) | ÷ | (564) |
| 2014. 12. 31. | — | = | 100 | × | 356) | ÷ | (704) |
| 2013. 12. 31. | — | = | 100 | × | 227) | ÷ | (667) |
보고서 기준: 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31).
1 US$ 단위: 백만 달러
경쟁사와의 비교
IQVIA Holdings Inc., ROE, 장기 추세, 경쟁사와의 비교
| IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022. 12. 31. | 18.92% | 68.60% | 178.97% | 20.37% | 14.39% | 58.64% | 21.62% | 23.36% | 31.57% | 32.79% | 19.14% | 15.80% | 23.88% |
| 2021. 12. 31. | 15.99% | 74.91% | 87.96% | 19.46% | 14.24% | 62.16% | 29.55% | 28.20% | 34.17% | 28.47% | 43.03% | 18.94% | 23.19% |
| 2020. 12. 31. | 4.65% | 35.30% | 77.20% | -23.84% | 9.17% | 109.79% | 0.68% | 23.25% | 27.91% | 15.21% | 31.86% | 18.47% | 31.22% |
| 2019. 12. 31. | 3.18% | — | 81.07% | 6.66% | 9.94% | 319.09% | 23.91% | 25.42% | 37.99% | 25.77% | 19.08% | 12.45% | 19.34% |
| 2018. 12. 31. | 3.86% | — | 67.15% | 35.07% | 9.40% | 32.88% | 25.51% | 25.60% | 23.30% | 17.59% | 27.91% | 10.65% | 47.28% |
| 2017. 12. 31. | 16.14% | 104.16% | 7.84% | 8.58% | 9.45% | -1.76% | 22.64% | 2.16% | 6.97% | 29.47% | 19.51% | 8.76% | 12.99% |
| 2016. 12. 31. | 1.33% | 128.41% | 25.85% | 27.55% | 11.10% | 19.54% | 71.48% | 23.49% | 9.78% | 12.12% | 20.13% | 9.39% | -9.69% |
| 2015. 12. 31. | — | 130.39% | 24.71% | 10.97% | 14.17% | 16.53% | 97.70% | 21.66% | 9.94% | 10.75% | 17.40% | 9.25% | -59.19% |
| 2014. 12. 31. | — | 101.84% | 20.01% | 13.49% | 11.11% | 15.55% | 78.45% | 23.40% | 24.50% | 12.81% | 13.69% | 9.22% | -68.70% |
| 2013. 12. 31. | — | 91.90% | 23.00% | 16.91% | 12.04% | 26.57% | 27.05% | 18.68% | 8.85% | 28.83% | 21.74% | 7.55% | -32.81% |
보고서 기준: 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31).
산업 부문과의 비교: 제약, 생명공학 및 생명과학
IQVIA Holdings Inc., ROE, 장기 추세, 산업 부문과 비교: 제약, 생명공학 및 생명과학
| IQVIA Holdings Inc. | 제약, 생명공학 및 생명과학 | |
|---|---|---|
| 2022. 12. 31. | 18.92% | 27.99% |
| 2021. 12. 31. | 15.99% | 29.75% |
| 2020. 12. 31. | 4.65% | 17.22% |
| 2019. 12. 31. | 3.18% | 27.68% |
| 2018. 12. 31. | 3.86% | 26.29% |
| 2017. 12. 31. | 16.14% | 14.59% |
| 2016. 12. 31. | 1.33% | 22.19% |
| 2015. 12. 31. | — | 21.44% |
| 2014. 12. 31. | — | 20.91% |
| 2013. 12. 31. | — | 20.33% |
보고서 기준: 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31).
업계와의 비교: 의료
IQVIA Holdings Inc., ROE, 장기 추세, 업계와의 비교: 의료
| IQVIA Holdings Inc. | 의료 | |
|---|---|---|
| 2022. 12. 31. | 18.92% | 22.47% |
| 2021. 12. 31. | 15.99% | 22.98% |
| 2020. 12. 31. | 4.65% | 16.02% |
| 2019. 12. 31. | 3.18% | 20.98% |
| 2018. 12. 31. | 3.86% | 17.71% |
| 2017. 12. 31. | 16.14% | 14.11% |
| 2016. 12. 31. | 1.33% | 18.09% |
| 2015. 12. 31. | — | 18.16% |
| 2014. 12. 31. | — | 18.60% |
| 2013. 12. 31. | — | 18.15% |
보고서 기준: 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31).